Giuseppe Cabibbo

10.1k total citations · 2 hit papers
128 papers, 3.7k citations indexed

About

Giuseppe Cabibbo is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Giuseppe Cabibbo has authored 128 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Hepatology, 77 papers in Epidemiology and 20 papers in Oncology. Recurrent topics in Giuseppe Cabibbo's work include Hepatocellular Carcinoma Treatment and Prognosis (83 papers), Liver Disease Diagnosis and Treatment (66 papers) and Hepatitis C virus research (32 papers). Giuseppe Cabibbo is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (83 papers), Liver Disease Diagnosis and Treatment (66 papers) and Hepatitis C virus research (32 papers). Giuseppe Cabibbo collaborates with scholars based in Italy, Spain and United States. Giuseppe Cabibbo's co-authors include Antonio Craxı̀, Calogero Cammà, Marco Enea, Massimo Attanasio, Jordi Bruix, Massimo Iavarone, Giacomo Emanuele Maria Rizzo, Antonio Grieco, María Reig and Claudio Zavaglia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Giuseppe Cabibbo

119 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

2022 246 citations Amit G. Singal, María Reig et al. Journal of Hepatology profile →
Hepatitis B Virus-Associated Hepatocellular Carcinoma

2022 112 citations Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo et al. profile →

Peers

Countries citing papers authored by Giuseppe Cabibbo

Since Specialization

Citations

This map shows the geographic impact of Giuseppe Cabibbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Cabibbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Cabibbo more than expected).

Fields of papers citing papers by Giuseppe Cabibbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppe Cabibbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Cabibbo. The network helps show where Giuseppe Cabibbo may publish in the future.

Co-authorship network of co-authors of Giuseppe Cabibbo

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppe Cabibbo. A scholar is included among the top collaborators of Giuseppe Cabibbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppe Cabibbo. Giuseppe Cabibbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hepatocellular carcinoma in people living with HIV 2025 ·Journal of Hepatology ·Claudia Angela Maria Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, (unknown), Matthias Pinter, Antonio D’Alessio, (unknown), Norbert Bräu, Mark Bower, David J. Pinato	0
2	Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 2025 ·Gut ·Ciro Celsa, Grazia Pennisi, (unknown), (unknown), (unknown), (unknown), (unknown), David J. Pinato, Giuseppe Cabibbo, Marco Enea, Alessandro Mantovani, Herbert Tilg, Giovanni Targher, Calogero Cammà, Salvatore Petta	7
3	Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 2025 ·JAMA Oncology ·Ciro Celsa, (unknown), Pasquale Lombardi, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, (unknown), Giulia Francesca Manfredi, Bernardo Stefanini, (unknown), Cristina Rigamonti, Mario Pirisi, (unknown), (unknown), Marco Enea, Calogero Cammà, Giuseppe Cabibbo, David J. Pinato	0
4	Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 2025 ·Clinical Gastroenterology and Hepatology ·Leonardo Stella, (unknown), Lucia Cerrito, Francesco Santopaolo, Francesco Tovoli, Clémence Hollande, (unknown), Bernardo Stefanini, Claudia Campani, Elisa Pellegrini, Giuseppe Cabibbo, Fabio Marra, Fabio Piscaglia, Antonio Gasbarrini, Maurizio Pompili, Mohamed Bouattour, Francesca Romana Ponziani	2
5	Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 2024 ·Clinical Cancer Research ·Giuseppe Cabibbo, Ciro Celsa, (unknown), Marco Enea, (unknown), (unknown), (unknown), Giulia Francesca Manfredi, Massimo Iavarone, Arndt Vogel, Amit G. Singal, María Reig, David J. Pinato, Calogero Cammà	6
6	Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity 2023 ·SHILAP Revista de lepidopterología ·Giuseppe Miceli, Grazia Pennisi, Luisa Agnello, Vincenza Calvaruso, Emanuele Amodio, Alessandra Casuccio, (unknown), (unknown), Rosaria Maria Pipitone, Mario Daidone, (unknown), (unknown), Salvatore Petta, Giuseppe Cabibbo, Marcello Ciaccio, Stefania Grimaudo, Antonio Craxı̀, Antonino Tuttolomondo	0
7	Systemic therapies for hepatocellular carcinoma: the present and the future 2021 ·Recenti Progressi in Medicina ·Ciro Celsa, (unknown), (unknown), (unknown), Federica Spatola, Giacomo Emanuele Maria Rizzo, (unknown), Roberto Cannella, Salvatore Battaglia, Calogero Cammà, Giuseppe Cabibbo	4
8	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 2021 ·Cancers ·Alessandro Vitale, Fabio Farinati, Michele Finotti, (unknown), Giuseppina Brancaccio, Fabio Piscaglia, Giuseppe Cabibbo, Eugenio Caturelli, Gabriele Missale, Fabio Marra, Rodolfo Sacco, Edoardo G. Giannini, Franco Trevisani, Umberto Cillo, (unknown), (unknown)	29
9	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting 2021 ·Journal of Clinical Medicine ·Maria Corina Plaz Torres, Quirino Lai, Fabio Piscaglia, Eugenio Caturelli, Giuseppe Cabibbo, Elisabetta Biasini, Filippo Pelizzaro, Fabio Marra, Franco Trevisani, Edoardo G. Giannini	15
10	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Stefania Grimaudo, Domenica Matranga, Massimo Attanasio, Paolo Bruzzi, Antonio Craxı̀, Calogero Cammà	16
11	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, (unknown), Domenica Matranga, Massimo Attanasio, María Reig, Antonio Craxı̀, Calogero Cammà	20
12	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis 2019 ·Expert Opinion on Drug Safety ·Giovanni Galati, (unknown), Mauro Viganò, Massimo Iavarone, Alessandro Vitale, (unknown), Quirino Lai, Giuseppe Cabibbo, Rodolfo Sacco, Erica Villa, Franco Trevisani	12
13	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 2018 ·Recenti Progressi in Medicina ·Giuseppe Cabibbo, M. Rossi, Ciro Celsa, Marcello Maida, Calogero Cammà	1
14	HBV virological suppression: still not enough to save from hepatocellular carcinoma. A case report on a 15-year, real-life story 2017 ·Recenti Progressi in Medicina ·Tullio Prestileo, Francesco Di Lorenzo, Adriana Sanfilippo, (unknown), Giuseppe Cabibbo, Salvatore Corrao	1
15	Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 2016 ·Journal of Hepatology ·(unknown), V. Di Marco, Massimo Iavarone, Luigi Roffi, Andrea Crosignani, Vincenza Calvaruso, Alessio Aghemo, Giuseppe Cabibbo, Mauro Viganò, V. Boccaccio, Antonio Craxı̀, Massimo Colombo, Patrick Maisonneuve	85
16	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 2015 ·Digestive and Liver Disease ·Andrea Mancuso, Alessandra Mazzola, Giuseppe Cabibbo, Giovanni Perricone, Marco Enea, Antonio Galvano, Claudio Zavaglia, L Belli, Calogero Cammà	46
17	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 2014 ·Default journal ·Daniela Cabibi, Giuseppe Cabibbo, Calogero Cammà, Antonio Craxı̀, Salvatore Petta, (unknown), V. Di Marco, Marcello Maida, Fabio Salvatore Macaluso	2
18	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report 2013 ·World Journal of Hepatology ·Marcello Maida, Fabio Salvatore Macaluso, Giuseppe Cabibbo, Giuseppe Lo Re, Nicola Alessi	6
19	Treatment of hepatocellular carcinoma: present and future 2013 ·Expert Review of Anticancer Therapy ·(unknown), Giuseppe Cabibbo, Marcello Maida, Giuseppe Brancatelli, Massimo Galia, Nicola Alessi, (unknown), (unknown), (unknown), Santi Maurizio Raineri, Antonino Giarratano, Massimo Midiri, Calogero Cammà	20
20	Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease 2008 ·Gastroenterology ·Flavia Bortolotti, Gabriella Verucchi, Calogero Cammà, Giuseppe Cabibbo, Lucia Zancan, Giuseppe Indolfi, R. Giacchino, Matilde Marcellini, Maria Grazia Marazzi, Cristiana Barbera, Giuseppe Maggiore, Pietro Vajro, S. Bartolacci, Fiorella Balli, Anna Maccabruni, Maria Guido	187

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact